Five-year recurrence-free rates of 89.4% and 83.9% indicate durable disease control after ProSense cryoablation in localized ...

Women with early-stage breast cancer who couldn't enter clinical trials of cryoablation because of "unfavorable" tumor or patient characteristics nevertheless enjoyed a high rate of treatment success ...

Use of the ProSense Cryoablation System in patients with kidney cancer resulted in an 83.9% recurrence-free rate among 112 ...

The FDA granted marketing authorization for the ProSense Cryoablation System for small, early-stage breast cancer in older women not suitable for surgery, maker IceCure announced. A minimally invasive ...

Cryoablation (also called cryosurgery or cryotherapy) uses very low temperatures to freeze abnormal tissue, destroying it during freezing. A medical professional uses a cryoprobe, which is cooled with ...

ICESECRET completed five-year follow-up after CT-guided ProSense cryoablation, with imaging-based surveillance for local recurrence and systematic capture of procedure-related complications.

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive ...

CAESAREA, Israel, Oct. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for patients ...

CAESAREA, Israel, March 18, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...

CAESAREA, Israel, March 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...